New Trial Results: Kiora's KIO-301 Demonstrates Meaningful Vision Improvements in Retinitis Pigmentosa

Technology

Kiora Pharmaceuticals specializes in developing and commercializing products for treating orphan retinal diseases. We’re excited about the products in the pipeline and the positive outcome they may bring to patients in need.

OUR PRODUCTS
These therapeutics are still in development and are not yet approved for commercial use.
NEWS
Loading RSS Feed